J&J's Janssen scores partial victory in second Risperdal trial

March 20, 2015 10:22 PM

5 0

J&J's Janssen scores partial victory in second Risperdal trial

NEW YORK (Reuters) - A Philadelphia jury on Friday found that Johnson & Johnson’s Janssen Pharmaceuticals failed to warn that antipsychotic drug Risperdal could cause male breast growth, in a case filed by a young man who had taken the drug, but it awarded no damages after finding no direct link to the man's condition.

The verdict came after a month-long trial in the Philadelphia Court of Common Pleas, according to Tom Kline of law firm Kline & Specter, who represented the plaintiff, William Cirba, 19, of Pennsylvania.

Read more

To category page

Loading...